GLP1R and obesity due to melanocortin 4 receptor deficiency: Semaglutide is a GLP-1R single agonist, similar to tirzepatide, that significantly improves hyperglycemia and obesity and has been approved by the FDA in 2021 as a weight loss drug for chronic weight management [18].